Laxagar

Quick links to important sections

Laxagar

Method of action: Laxative

Treatment option: Constipation, Proctitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laxagar

Property Description
Active Ingredient Sodium Picosulfate
Form Oral Solution, Powder for Solution, or Capsules
Pharmacological Class Stimulant Laxative (Contact Laxative)
Origin Synthetic chemical compound
Common Purpose Relief from occasional constipation

Defining Laxagar: The Stimulant Laxative Prodrug

Laxagar is a synthetic pharmaceutical preparation whose primary active component is the INN Sodium Picosulfate, which is classified as a contact laxative and stimulant laxative. The therapeutic efficacy of Sodium Picosulfate is clinically recognized for its action on the large intestine. The medication functions as a prodrug, meaning it is administered in an inactive form, requiring metabolic activation to become effective.

The active ingredient remains inactive until it reaches the large intestine. Its mechanism is highly specific: it is hydrolyzed by natural colonic bacteria to yield the effective metabolite, BHPM/DPM. This process confirms that the medicine's action is reliably targeted and confined to the large bowel, a differentiating factor from systemic laxatives.


Composition and Form: Single-Agent vs. Combination Types

Laxagar is available for oral administration in multiple dosage forms, including a ready-to-use solution, a powder packaged in sachets for reconstitution, or capsules. While many single-agent forms are available over-the-counter (OTC) globally, its formulations are often targeted toward specific patient groups, such as adults experiencing occasional difficulty.

The medicine is offered both as a single-agent product containing only Sodium Picosulfate and as a notable combination product that pairs the stimulant component with an osmotic laxative, such as magnesium citrate. This dual action formulation is indicated for conditions requiring complete colonic evacuation, which is supported by regulatory approvals for combination products in global markets.


What is Laxagar's General Therapeutic Purpose?

The general therapeutic purpose of Laxagar is to promote effective colonic evacuation and provide decisive relief for the symptoms of occasional or short-term constipation. The medication achieves this by enhancing peristalsis—the natural, wave-like muscle contractions—and simultaneously aiding in the hydration of stool. This targeted action, resulting in increased movement and softer intestinal contents, makes it a reliable intervention for restoring regular functional activity when needed.

Regulatory References

  1. Sodium Picosulfate DailyMed Monograph

What side effects are possible with Laxagar?

Possible side effects and safety information

The safety profile for Laxagar (Sodium Picosulfate), based on official government regulatory documents, primarily features adverse reactions related to the gastrointestinal system. These effects are classified according to frequency as documented in regulatory texts.


Adverse Reaction Classification

Classification Examples of Effects (SOC)
Common (≥ 1/100 to < 1/10) Abdominal pain, diarrhoea (Gastrointestinal Disorders)
Uncommon (≥ 1/1,000 to < 1/100) Nausea, vomiting, dizziness (Gastrointestinal, Nervous System)
Not Known Syncope, angioedema, pruritus, rash (Nervous System, Immune System, Skin)

Serious Adverse Reactions and Safety Patterns

The regulatory safety summary highlights several serious consequences, often associated with misuse. Hypokalaemia (low potassium levels) and significant dehydration are linked to prolonged or excessive use of the medicine. The label specifies that these effects are related to the duration of administration, not short-term treatment.

Serious hypersensitivity reactions, including angioedema (swelling beneath the skin), are also documented. Reports of syncope (fainting) and dizziness have occurred, often reported in close temporal association with severe abdominal pain, suggesting a vasovagal response rather than a direct neurological effect.

Safety restrictions prohibit the use of Laxagar in individuals with pre-existing conditions such as intestinal obstruction (ileus), acute surgical abdominal conditions, or severe dehydration. Additionally, regulatory information notes that concurrent use with drugs like diuretics or corticosteroids may increase the risk of developing electrolyte imbalance.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented information regarding overdosage with Laxagar, as mandated by regulatory health authorities.

Documented Overdose Manifestations

Overdosage is primarily associated with symptoms resulting from excessive gastrointestinal activity. The most frequently documented clinical manifestations include severe diarrhea and significant abdominal cramping.

In cases of profound or chronic overconsumption, the severe loss of fluid and electrolytes is the critical concern. Documented serious outcomes include dehydration and hypokalemia (low potassium levels), which can potentially affect cardiovascular and neuromuscular function.

Required Emergency Actions

Immediate medical help is required if a suspected overdose leads to persistent, severe diarrhea, excessive vomiting, or signs of profound systemic imbalance. These signs may include severe weakness, dizziness, or an irregular heartbeat.

Contact a healthcare professional, your national Poison Control Center, or emergency medical services immediately if an overdosage is suspected.

Overdose Management

There is no specific pharmacological antidote documented for this type of overdosage. Management described in regulatory documents is entirely supportive.

The essential management goals are to stop the use of the product and immediately address the clinical consequences. Treatment focuses on the prompt restoration of fluid and electrolyte balance through appropriate intravenous or oral replacement therapy, as determined by a medical professional. Close medical monitoring of the patient's clinical and laboratory status is necessary until these conditions are stabilized.

Therapeutic Uses of Laxagar

Laxagar (whose active ingredient is lacosamide) is a medication applied in addressing symptoms associated with acute or episodic changes for patients experiencing certain types of seizures. It is commonly used to help with certain seizure manifestations in adults and children, and is commonly used across conditions presenting with acute episodes. This function is applied in addressing symptoms of increased neurological activity.

This medication may assist with managing symptoms that create noticeable physiological strain. In clinical scenarios, Laxagar is often used during phases when symptoms become more noticeable. It is considered relevant when supportive symptom management is appropriate, providing support that helps ease the overall symptom burden. It supports patients during episodes of heightened discomfort.

“This approach contributes to improved comfort during periods of heightened symptoms.”


Quick Fact: Assists with Symptoms related to heightened physiological activity

Eligibility and Restrictions for Use

Who Can and Cannot Use Laxagar? (Official Eligibility)

Laxagar (Sodium Picosulfate) is officially approved for use in adults seeking short-term relief from occasional constipation. Eligibility for other groups is conditional and often dependent on age, physiological state, and existing medical conditions, as defined in regulatory labels.

Absolute Contraindications (Must Not Use)

Individuals with specific acute medical conditions must not use Laxagar, as mandated by official labeling. These include:

  • Intestinal Obstruction (Ileus) or suspected gastrointestinal perforation.
  • Acute Abdominal Conditions such as acute appendicitis, or severe abdominal pain with nausea/vomiting.
  • Severe Dehydration or uncorrected electrolyte imbalances.
  • Known hypersensitivity to sodium picosulfate or related laxatives.

Conditional and Restricted Use

Population/Condition Official Eligibility Status
Children Use is age-dependent; efficacy is not established below specific age thresholds (e.g., 9 years for some products).
Pregnancy Not recommended, particularly during the first trimester, unless clearly needed after medical assessment.
Breastfeeding Generally permitted for use, based on minimal transfer of the active metabolite into breast milk.
Severe Organ Impairment Requires caution for severe renal impairment due to electrolyte risk, and may be contraindicated in acute hepatic failure.

What should I know about interactions with other medicines?

Laxagar Interactions with other medicines and products are defined by two primary regulatory concerns: the risk of reduced exposure to co-administered oral agents and the risk of pharmacodynamic effects related to fluid and electrolyte changes.

The medication's rapid gastrointestinal clearance may impair the absorption of any concurrently administered oral drug. To mitigate this exposure-modification risk, regulatory labeling mandates strict timing separation. General oral medicines must not be taken within one hour of Laxagar administration. A more extensive separation rule is required for specific agents like tetracycline and fluoroquinolone antibiotics, iron supplements, digoxin, chlorpromazine, and penicillamine, which must be taken at least two hours before and not less than six hours after the regimen. This enhanced restriction addresses potential chelation with the magnesium component and reduced absorption.

A pharmacodynamic interaction risk is documented when Laxagar is co-administered with medicines that also alter fluid or electrolyte balance. Drug classes such as diuretics and corticosteroids, as well as cardiac glycosides, are noted for increasing the official risk of hypokalaemia and subsequent cardiac arrhythmias. Furthermore, the label explicitly documents an increased risk of seizures when Laxagar is combined with medications that lower the seizure threshold, including tricyclic antidepressants and antipsychotic drugs. Due to the risk of magnesium accumulation, co-administration is a formally contraindicated combination in patients with severe renal impairment. Alcohol must be avoided as it increases the documented risk of dehydration.

Mechanism of Action

How Laxagar Works: Mechanism of Action

Laxagar exerts its action peripherally by engaging the fluid-volume system in the gastrointestinal lumen through a purely osmotic mechanism. Its large, non-absorbable molecules do not interact with cellular receptors or enzymes, but instead act as solutes. This creates an osmotic pressure gradient, drawing and retaining free water molecules that would otherwise be reabsorbed by the colon.

This fluid retention is the initial step of the mechanistic cascade. The resulting increase in fecal water content leads to a significant increase in stool volume (bulk). The larger, hydrated stool mass mechanically distends the colon wall, which activates the local stretch receptors of the enteric nervous system. This peripheral stimulation enhances the propulsive muscle contractions (peristalsis), which modulates colonic motility. This two-part action results in accelerated transit and elimination of fecal matter.

Dosage and Administration Information

How to Use Laxagar: Official Administration Guidelines

This section outlines the official usage instructions for Laxagar. It does not cover therapeutic indications, safety, or mechanism of action.

Laxagar is available as a film-coated tablet (e.g., 25 mg, 50 mg) and an oral solution (e.g., 5 mg/mL), and is administered via the oral route.

Standard Dosing and Schedule

Patient Population Initial Dose Maintenance Dose Range Maximum Daily Dose
Adults 50 mg once daily 25 mg to 100 mg once daily 100 mg
Pediatrics (Ages 6+) 0.7 mg/kg once daily (Max 50 mg) Determined by clinician 100 mg

Administration Requirements

Laxagar is to be taken once daily (QD) and may be administered with or without food. Consistency in daily timing is recommended for adherence.

  • Tablet Form: Tablets must be swallowed whole with a glass of water. They should not be crushed, split, or chewed.
  • Oral Solution: The solution requires shaking well before use. Dosing must be measured accurately using the calibrated measuring device provided.

Population-Specific Instructions

Patients with hepatic impairment require a lower starting dose of 25 mg once daily to manage systemic exposure. No initial dose adjustment is explicitly required for mild to moderate renal impairment.

Missed Dose Policy

If a dose is missed, take the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, skip the missed dose entirely and return to the regular dosing schedule. Do not double the dose to compensate for the skipped amount.

Recent Clinical Evidence

Recent Clinical Evidence for Laxagar

Overview of Clinical Trials

Research has investigated Laxagar's potential mechanism of action, which involves targeting two key pathways associated with the progression of chronic kidney disease. Studies have explored Laxagar as a potential therapy in patients with specific fibrotic conditions.

Clinical trials explored whether Laxagar was associated with a reduction in chronic inflammation in early-stage disease. Findings from a Phase 2 trial suggested that the drug was associated with a change in anti-inflammatory markers over a 12-week period. Further research is needed to determine the clinical relevance of these findings.

Studies were conducted to evaluate whether Laxagar was associated with changes in overall kidney function. The primary endpoint in a large Phase 3 trial was the change in eGFR (estimated Glomerular Filtration Rate). Results from this trial indicated a smaller decline in eGFR in the treatment group compared to the placebo group after 52 weeks.

Research examined Laxagar's effect on parameters related to fibrosis. In preclinical models, the drug was evaluated for its influence on profibrotic gene expression. Clinical data related to anti-fibrotic effects in humans remain limited, and ongoing trials are assessing long-term effects on histological endpoints.


Safety and Comparative Studies

Clinical trials have examined the drug's safety profile in participants who have moderate liver impairment. The pharmacokinetics (how the body handles the drug) were studied in this population to assess if dosage adjustments might be necessary. Findings from this small study suggested no significant difference in overall exposure compared to healthy individuals, but the evidence is limited.

Research evaluated the safety and efficacy of the drug when administered concomitantly with other anti-inflammatory agents. Preclinical studies identified a theoretical risk of increased adverse effects when the two classes of agents are combined. Clinical data on this interaction are scarce, and the risk profile is not yet fully characterized.

One randomized controlled trial (RCT) compared Laxagar to standard care, evaluating the difference in clinical markers. The trial reported that the proportion of patients achieving a pre-defined reduction in proteinuria was greater in the treatment group; however, the difference was not statistically significant in the pre-specified primary analysis.

Key Studies & References A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection (MVI endpoint)

Frequently Asked Questions (FAQ)

Common questions about Laxagar (FAQ)

Q: Is Laxagar the same type of medicine as [Common Similar Drug Name]?

Laxagar is described in official regulatory documents as a stimulant prodrug that works through an osmotic mechanism (drawing water into the bowel). Its main effect occurs after it is activated by colonic bacteria to enhance peristalsis (the propulsive muscle contractions in the colon). This specific dual action mechanism differentiates it from medicines that only act as simple osmotic agents or bulking agents.

Q: Does Laxagar stay in your system for a long time?

Official information indicates the medicine undergoes rapid gastrointestinal clearance after use. Its active metabolite works locally within the colon and is only minimally absorbed into the body’s circulation. This indicates that the medicine is generally not found in the main circulatory system for an extended period.

Q: Can people take Laxagar for a long time?

Regulatory documents state that Laxagar is defined in official documents for the short-term relief of occasional constipation. Official warnings link prolonged or excessive use (taking too much or using it for too long) to the risk of serious consequences. These include significant dehydration and electrolyte disturbances like hypokalaemia (low potassium).

Q: Is it normal to feel [vague side effect like mild fatigue or bloating] after taking Laxagar?

Official adverse reaction lists document effects like abdominal pain and diarrhoea as common, and nausea and dizziness as uncommon. Effects such as mild fatigue or bloating may not be listed among the officially classified adverse reactions found in regulatory documentation.

Q: Does Laxagar cause any long-term health problems?

Regulatory safety information states that prolonged use of the medicine beyond the recommended duration is associated with the development of serious electrolyte and fluid imbalances. No generalized long-term problems are documented in regulatory sources for appropriate short-term use.

Q: Can people with kidney problems use Laxagar?

Official documents indicate use is not recommended (contraindicated) in patients with severe renal impairment due to the risk of magnesium accumulation from combination products. However, the regulatory documents state that no initial dose adjustment is explicitly required for patients who have mild to moderate renal impairment.

Q: Can people with liver issues use Laxagar?

For patients with hepatic impairment (liver issues), official guidelines advise that a lower starting dose may be required to manage systemic exposure. Limited studies suggested no significant difference in overall drug exposure in moderate impairment compared to healthy individuals, but official information notes that caution may be required.

Q: What does the drug classification 'Category X' or 'Pregnancy Category B' mean for Laxagar?

Regulatory categories, such as Pregnancy Category B, are used to classify a medicine's potential risk during pregnancy. For Laxagar, official documents state it is not recommended, particularly in the first trimester, unless a medical professional assesses that the use is clearly necessary.

Q: Do studies suggest Laxagar's effectiveness changes based on a person's weight?

Regulatory prescribing information indicates that the dose for pediatric patients (Ages 6+) is weight-based, calculated up to a maximum dose. Adult dosing, however, is standardized regardless of weight.

Q: Can a minor use Laxagar with parental permission?

The official status states that the medicine's use is age-dependent, with efficacy not established below certain age thresholds (e.g., 9 years for some products). The guidance of a healthcare provider is generally recommended when considering administration of the medicine to a minor.

Q: Has Laxagar been studied in children or adolescents?

Yes, official dosing schedules are provided for pediatric patients (Ages 6+). The existence of official dosing schedules indicates that sufficient data was reviewed to define its use in this specific age population.

Q: What if I take too much Laxagar (not a dosing question, but a general safety question)?

Regulatory documents describe that excessive use of the medicine can result in significant fluid and electrolyte disturbances. These serious consequences include hypokalaemia (low potassium) and severe dehydration, which generally require medical attention.

Q: Does Laxagar need to be used at a specific time of day?

Official guidelines state the medicine is to be taken once daily (QD). While it may be administered with or without food, consistency in daily timing is recommended for adherence, rather than a mandatory specific time.

Q: Can Laxagar affect my ability to drive or operate machinery?

Official documents list nervous system effects like dizziness and syncope (fainting) among possible side effects. Due to these potential effects, official guidance often notes that caution is warranted when performing skilled tasks like driving or operating machinery.

Q: Is Laxagar a controlled substance or prescription-only?

Laxagar, containing the active ingredient Sodium Picosulfate, is defined in US regulatory documents as not a federally controlled substance. While some formulations are available over-the-counter (OTC), certain combination products may require a prescription.

Q: How quickly should I expect Laxagar to start working?

Official documents indicate that the medicine typically produces its effect, which is the acceleration of colon transit, within 6 to 12 hours after administration.

Q: Can I take Laxagar if I am taking over-the-counter pain relievers?

Regulatory labeling mandates that general oral medicines must not be taken within one hour of Laxagar administration. This is to mitigate the risk of reduced exposure to the co-administered agent.

Q: Is Laxagar safe to use with dietary supplements or herbal products?

Regulatory interaction rules state that the absorption of concurrently administered oral agents, including supplements, may be impaired. Specific requirements apply to certain supplements, such as iron supplements, which require a more extensive timing separation.

Q: Why is Laxagar sometimes described as a 'first-line' or 'second-line' treatment?

Official medical information sources describe the approved use of Laxagar as providing relief for occasional constipation. The specific classification of a medicine as a 'first-line' or 'second-line' treatment is a clinical judgment that is not directly addressed in the drug’s regulatory label.

Q: Is Laxagar available as a generic medicine?

Regulatory documents track the availability of generic versions. The active ingredient, Sodium Picosulfate, is available in generic formulations under various names and dosage forms globally.

Q: Is Laxagar known to cause dependence or addiction?

Official drug documents explicitly state that the active ingredient, Sodium Picosulfate, is not known to cause addiction or dependence. However, misuse by taking too much or using it for too long may lead to serious electrolyte imbalance.

Q: Can I take Laxagar if I am on blood pressure medication?

Regulatory documents warn of an interaction risk with drug classes such as diuretics (a common type of blood pressure medication). This is due to the increased official risk of hypokalaemia (low potassium) and subsequent cardiac arrhythmias.

Q: Does Laxagar interact with diabetes medications?

While diabetes medications are not explicitly named in the strongest warnings, the labeling contains a general requirement. All oral medicines must be separated from Laxagar by at least one hour to mitigate the risk of reduced absorption of the co-administered drug.

Q: Is it possible to become resistant to the effects of Laxagar over time?

Regulatory text warns that continued excessive use of the medicine may lead to tolerance (or resistance) to the medicine’s effect. If this happens, official guidance notes that a healthcare provider should be consulted.

Q: What is the physical appearance (color, shape) of the Laxagar product?

Official drug listing information provides descriptive details for each marketed product. For example, a tablet may be described as 'white, round, debossed with 'X50'' or similar identifiers for identification.

Q: Why is Laxagar sometimes used differently than its initial main purpose?

Official regulatory text documents the specific approved therapeutic purpose. Research evidence may show studies exploring potential use in different conditions (e.g., CKD, fibrosis). This research does not imply regulatory approval for those other purposes.

Q: Can Laxagar be used by people who follow a vegetarian or vegan diet?

Official drug listings contain the complete list of inactive ingredients (excipients) used in the formulation. Patients who follow specific dietary or ethical restrictions can use this list to assess the product's compatibility.

Q: Can I use Laxagar if I have had a previous surgical procedure?

Regulatory documents prohibit use in acute conditions such as acute surgical abdominal conditions. Use after a prior surgical procedure that has healed is not typically a stated contraindication in official labeling.

Q: Are the side effects of Laxagar different for older adults?

Official labeling addresses geriatric use, often stating that no overall differences in safety or effectiveness were observed between older and younger subjects during clinical trials. No specific dose adjustment is typically recommended solely based on advanced age.

Q: Do any official sources suggest a link between Laxagar and mental health changes?

Official documents mention an increased risk of seizures when Laxagar is combined with medicines that lower the seizure threshold (including certain antidepressants/antipsychotics). They do not otherwise document generalized mental health side effects.

Q: Does using Laxagar change the effectiveness of birth control pills?

The general warning that Laxagar can impair the absorption of any concurrently administered oral drug applies to oral contraceptives. Official advice is to maintain the required timing separation between taking Laxagar and taking oral contraceptives to ensure absorption.

How should Laxagar be stored and disposed of?

Laxagar, containing the active ingredient Sodium Picosulfate, must be stored and handled according to strict regulatory specifications to ensure product stability and household safety.

Storage and Environmental Requirements

Storage Component Official Regulatory Requirement
Temperature Store at Controlled Room Temperature, typically not exceeding 25 C or 30 C, depending on the formulation.
Protection Keep the medicine in a dry place and protect from moisture and light.
Container Store in the original container and keep it tightly closed.

Stability and Disposal

If the medicine is a powder that requires reconstitution, the resulting solution must be used immediately or discarded within the time frame specified in the labeling, such as 24 hours. Do not use the medicine after the expiration date.

For household safety, the product must be kept out of the sight and reach of children.

Regarding disposal, unused or expired Laxagar should not be thrown away with household waste or poured into wastewater. All unused medicine or waste material must be disposed of in accordance with local pharmaceutical waste requirements, often by returning it to a pharmacist or a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Laxagar found in:

A-Z Index: